Every year, thousands of Indian families find themselves in the same heartbreaking situation. An oncologist has identified a treatment — one that has shown meaningful results in clinical trials, one that is approved and available in the United States or Europe, one that could be the right next step for their patient. And then comes the sentence that changes everything in the conversation.
“This medicine is not yet available in India.”
For families already navigating a cancer diagnosis, this feels like a wall. In reality, it is more often a door that most people simply do not know exists.
This article explains that door — what it is, how it opens, and what Indian patients and families need to do to walk through it.
Why Some Cancer Medicines Are Not Available in India
Global pharmaceutical development moves faster than any single country’s regulatory approval process. A cancer medicine that completes its pivotal clinical trial, receives approval from the US Food and Drug Administration or the European Medicines Agency, and begins reaching patients in Western markets may take several more years to receive marketing authorisation from India’s Central Drugs Standard Control Organisation (CDSCO) — if it ever does.
The reasons are not sinister. Regulatory review takes time. Clinical data packages must be submitted and evaluated. Some manufacturers prioritise larger markets first. Some medicines serve patient populations small enough that the commercial case for a full Indian registration process is difficult to make.
The result is a gap — a window of time, sometimes years, during which a medicine that could help an Indian patient is approved and available internationally but not accessible through normal channels in India.
That gap is not a dead end. It has a formal solution.
The Named Patient Program — What It Is
A Named Patient Program (NPP) is a regulatory pathway that allows a specific, named patient in India to access a medicine that has not received marketing authorisation in India, based on a clinical need that cannot be met by currently approved medicines.
Under an NPP, the medicine is imported specifically for that individual patient — not for general distribution, not for stock, but for one person whose treating specialist has determined that this particular medicine is clinically appropriate for their situation and that no approved equivalent exists in India for their specific need.
The pathway is legal, regulated, and established. It exists precisely because regulators recognise that the gap between global approval and local approval should not automatically mean that patients in that gap go without access to medicines that might help them.
For families who have been told that the medicine their oncologist is recommending is not available in India, the Named Patient Program is often the answer to the question they did not yet know to ask.
How the Named Patient Program Works in Practice
The NPP process is more structured than simply ordering a medicine from abroad. It involves several steps, and the most important thing families can do is understand those steps in advance rather than trying to navigate them under the pressure of a time-sensitive treatment decision.
Step 1 — The treating specialist initiates the process
The NPP begins with the oncologist, not with the patient or their family. A qualified specialist must provide a detailed clinical justification explaining why the specific medicine is needed, why no approved alternative in India is adequate for this patient’s situation, and what the proposed treatment plan involves. This justification is not a formality — it is a clinical document that forms the basis of the import application.
Step 2 — Confirming that no approved Indian equivalent exists
The NPP is specifically for medicines not available in India for the relevant indication. If an approved medicine with a similar mechanism exists in India, the NPP for the non-approved alternative is generally not the right pathway. The treating specialist will advise on whether the specific medicine in question qualifies.
Step 3 — Working with a licensed specialty distributor
Once the clinical documentation is in place, the import of the medicine itself requires a licensed pharmaceutical distributor with the specific capability and authorisation to handle named patient imports. This is not something a general pharmacy or general wholesaler can facilitate — it requires a distributor with direct relationships with the manufacturer or their authorised channels, experience navigating import documentation, and cold chain infrastructure if the medicine requires refrigeration.
Step 4 — Patient consent and documentation
The patient or their authorised representative typically provides consent documentation confirming their understanding of the treatment and the import process. Full documentation requirements vary depending on the specific medicine and the import pathway applicable to it.
Step 5 — Import and delivery
The medicine is imported specifically for the named patient and delivered to the treating hospital or clinic, accompanied by complete documentation including batch number, expiry date, and certificate of analysis. The treating physician administers or dispenses the medicine within the clinical setting.
What Families Should Realistically Expect
The NPP pathway is real and it works — but families approaching it need a clear understanding of what to expect, because approaching it with unrealistic expectations creates additional distress at an already difficult time.
Timelines vary. Importing a medicine through an NPP is not the same as a standard prescription being filled at a pharmacy. Depending on the medicine, the manufacturer, current stock availability, and the documentation process involved, the timeline from initiating the process to having the medicine in hand can range from days to several weeks. Starting the conversation with the treating specialist and a specialist distributor as early as possible — not when treatment is urgently needed tomorrow — is the single most important practical step.
Cost is real. Medicines imported through NPP pathways are typically more expensive than medicines with local Indian marketing authorisation, because the import process involves additional logistics, documentation, and supply chain costs. The exact cost depends on the medicine and the specific import pathway. Patient assistance programs sometimes exist for medicines available through NPP that can offset some or all of the cost — this is worth asking about specifically.
Not every medicine qualifies. The NPP is for medicines that are not available in India through any approved channel for the relevant indication. It is not a route to access medicines that are available in India but are simply difficult to find locally, or medicines that are approved for one indication in India but are being sought for a different indication.
The treating specialist must lead. Families cannot initiate an NPP independently. The clinical justification must come from a qualified specialist who takes clinical responsibility for the prescription. Attempting to source a medicine through informal channels abroad without this clinical and regulatory framework is both legally risky and medically dangerous — there is no quality assurance, no chain-of-custody documentation, and no clinical oversight in that pathway.
The Patient Assistance Program — A Different but Related Pathway
The Named Patient Program is sometimes confused with a Patient Assistance Program (PAP), and the distinction matters.
A Patient Assistance Program applies to medicines that are already approved and commercially available in India — the barrier is cost, not availability. A manufacturer-supported PAP can make an approved but expensive medicine available at reduced or zero cost to patients who meet specific eligibility criteria, typically centred on financial need.
An NPP applies when the medicine is not available in India at all — the barrier is access, not cost.
Both programs exist. Both serve patients who would otherwise go without a medicine they need. And both require navigation through a licensed specialty distributor and the treating clinical team — they cannot be accessed independently by patients or families.
Full information on both pathways is available at A.K. Pharma’s Patient Assistance Program and Named Patient Program pages.
What Families Should Do Right Now
If you are reading this because a family member’s oncologist has mentioned a cancer medicine that is not available in India, the most useful immediate steps are:
Ask the oncologist directly: Is the medicine they are recommending available through a Named Patient Program? What documentation would be needed to initiate the process? Are they aware of any patient assistance support available for this medicine?
Contact a licensed specialty distributor: A distributor with experience in named patient imports can give you a realistic picture of the timeline, cost, and documentation process for the specific medicine in question. This conversation is worth having early — not when treatment is immediately urgent.
Do not attempt to source the medicine informally. Purchasing cancer medicines from unverified online sources, through personal contacts abroad, or through any channel outside the NPP framework removes every protection that exists in the formal pathway — quality verification, cold chain assurance, documentation, and clinical oversight. The risk is not worth taking with a medicine that is going to be administered to a patient who is already seriously ill.
Start early. The NPP process takes time. The families who navigate it most successfully are the ones who begin the conversation weeks before the treatment is urgently needed, not days after.
A Final Word on What Is Possible
The gap between global approval and Indian availability will always exist to some degree. Regulatory timelines, commercial decisions, and the complexity of international pharmaceutical registration mean that Indian patients will sometimes need medicines that are not yet formally available here.
But that gap does not have to mean no access. The Named Patient Program exists precisely to bridge it — formally, safely, and with full clinical and regulatory accountability. For the families navigating a cancer diagnosis who have been told that the right medicine is not available in India, knowing that this pathway exists — and knowing how to access it — can change everything.
For more information on Named Patient Program and Patient Assistance Program access for specialty and imported medicines in India, visit akpharma.in or contact A.K. Pharma at 011 4172 6999.
Disclaimer: This article is intended for general informational purposes only and does not constitute medical or legal advice. All decisions about cancer treatment, including access to medicines through Named Patient Programs, should be made in consultation with a qualified oncologist and the appropriate regulatory and distribution channels. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.